MicroRNA Therapeutics in Triple Negative Breast Cancer
نویسنده
چکیده
Breast cancer is a complex disease and one of the main causes of cancer-related mortality in women worldwide. In case of approximately 15% of all breast cancers, three markers i.e. estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptors-2 (HER2) are not express, and is commonly termed as triple-negative breast cancer (TNBC). Particularly, TNBC is associated with a higher percentage of breast cancer related mortality, which is often aggressive and most frequently found with a BRCA1 mutation or increased basal marker expression. However, due to the limitations of chemotherapy and radiation based treatment; the current challenge is to establish a new strategy of diagnosis and treatment of TNBC. The deregulation of a number of microRNAs (miRNAs) in breast cancer has been widely reported. Therefore, this review is directed towards enhancing our understanding of the involvement of various miRNAs in the pathology of TNBC, their upregulations and downregulations and the effects on various factors. From recent studies a number of miRNAs are found to be related with TNBC, which have great potential to be used as a biomarker to determine the disease prognosis and predict the fate of disease. Again miRNA can be targeted to be applied as a therapeutic to provide a great benefi t to the patients of TNBC by fi nding a new, safe, and effective treatment strategy. Review Article
منابع مشابه
Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملMicroRNA therapeutics in preclinical cancer models.
www.thelancet.com/oncology Vol 12 April 2011 319 was not a substantial change in KRAS mRNA in KRASvariant triple-negative tumours, Paranjape and colleagues reported an enrichment of both the NRAS mutant and MAP-kinase-activation signatures in tumours that had the polymorphism. Moreover, in line with previous reports in non-small-cell lung cancer, expression of let-7 family members was lower in ...
متن کاملEpigenetic Regulation of microRNA Expression: Targeting the Triple-Negative Breast Cancer Phenotype PRINCIPAL INVESTIGATOR:
متن کامل
Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression
Transforming growth factor-β1 is considered a key contributor to the progression of breast cancer. MicroRNAs are important factors in the development and progression of many malignancies. In the present study, upon studies of breast cancer cell lines and tissues, we showed that microRNA -196a-3p is decreased by transforming growth factor-β1 in breast cancer cells and associated with breast canc...
متن کاملFrom microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment
MicroRNAs (miRNAs or miRs) are a family of small non‑coding RNAs that regulate gene expression by the sequence-selective targeting of mRNAs, leading to translational repression or mRNA degradation, depending on the degree of complementarity with target mRNA sequences. miRNAs play a crucial role in cancer. In the case of breast tumors, several studies have demonstrated a correlation between: i) ...
متن کاملThe Clinical and Prognostic Significance of Triple-Negative Status Invasive Breast Cancer in a Sample of Iraqi Women
Introduction: Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor, progesterone receptor, and HER2. This study aimed to evaluate the clinical outcomes and short-term prognosis of this type of cancer compared with other subtypes of breast cancer. Methods: A cross-sectional study was conducted on 108 women with invasive breast cancer. The patie...
متن کامل